Kardigan (USA) Funding: $300M - medicalstartups.org

Jan 14, 2025 · Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom …

CouponFollow Extension

$300
OFF

Kardigan (USA) Funding: $300M - Medicalstartups.org

2 weeks from now

Jan 14, 2025 · Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom …

medicalstartups.org

$300
OFF

Kardigan Raises $300m For Cardio Work, And Other Financings

2 weeks from now

Jan 31, 2025 · Kardigan makes its debut with a team of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.

pharmaphorum.com

$300
OFF

Kardigan Launches With Cozy $300M, Late-stage Portfolio

2 weeks from now

Jan 10, 2025 · Kardigan will use the funds to knit together a pipeline focused on unmet needs in cardiology, with multiple late-stage candidates already in hand.

fiercebiotech.com

$300
OFF

Kardigan Debuts With $300M And Visionary Team To Revolutionize ...

2 weeks from now

San Francisco & Princeton, NJ, January 10, 2025 (Business Wire) -- Kardigan launches with $300 million in funding and a mission to cure and prevent cardiovascular disease, led by Tassos …

jacobsmgt.com

$300
OFF

Kardigan Launches With $300 Million Series A To Transform ...

2 weeks from now

Jan 13, 2025 · Combining its leading-edge discovery and translational research platform with strategic in-licensing and acquisitions, Kardigan is building a fully integrated biopharmaceutical …

biopharmaboardroom.com

$300
OFF

Kardigan, Founded By Veterans Of MyoKardia, Raise $300M For New …

2 weeks from now

Jan 10, 2025 · Trio behind MyoKardia raise $300 million for new biotech firm focused on heart disease.

statnews.com

$300
OFF

MyoKardia Alumni Launch Kardigan With $300M To Tackle Heart …

2 weeks from now

Jan 10, 2025 · After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make …

biospace.com

$300
OFF

Kardigan - Raised $300M Funding From 3 Investors - Tracxn

2 weeks from now

5 days ago · How much funding did Kardigan raise in its latest funding round? Kardigan raised $300M in its latest funding round, which was Series A round held on Jan 13, 2025.

tracxn.com

$300000000
OFF

Founder Lodge | Kardigan Raises $300,000,000 At Series A On 2025 …

2 weeks from now

14/01/2025 Series A $300,000,000 Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond …

founderlodge.com

$300
OFF

Kardigan Launches With Cozy $300M Series A And Collection Of Late …

2 weeks from now

Jan 11, 2025 · A new company is making its debut with a series A sum that’s sure to make hearts race. Launching with $300 million in hand, Kardigan plans to develop parallel treatments to …

sfbn.org

$300
OFF

Kardigan: $300 Million Raised For Modernizing Cardiovascular …

2 weeks from now

Jan 13, 2025 · Kardigan - a heart health company modernizing cardiovascular drug development - announced it launched with a mission to develop multiple targeted treatments in parallel, …

pulse2.com

$300000000
OFF

Founder Lodge | Kardigan Raises $300,000,000 At Series A On 2025 …

2 weeks from now

Jan 14, 2025 · Kardigan raises $300,000,000 at Series A on 2025-01-14 in Biotechnology Research, industry founded/co-founded by Tassos Gianakakos

founderlodge.com

FAQs about Kardigan (USA) Funding: $300M - medicalstartups.org Coupon?

Why is kardigan developing new medicines?

Cardiovascular disease is the leading cause of death in the world. We are developing novel medicines to change that. Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. ...

Does kardigan have a plan to cure cardiovascular disease?

Launching with $300 million in hand, Kardigan plans to develop parallel treatments to prevent and cure cardiovascular diseases so that they’re no longer the leading cause of death worldwide, the company announced in a Jan. 10 release. Investors include Perceptive Advisors, Arch Venture Partners and Sequoia Heritage. ...

What is a kardigan series a?

A new company is making its debut with a series A sum that’s sure to make hearts race. Launching with $300 million in hand, Kardigan plans to develop parallel treatments to prevent and cure cardiovascular diseases so that they’re no longer the leading cause of death worldwide, the company announced in a Jan. 10 release. ...

How does kardigan's R&D platform work?

Kardigan’s R&D platform uses a proprietary set of cardiac-specific tools to understand the mechanisms behind its therapeutic candidates as well as the individual responses patients have to treatments, the company said. ...

How much money does kardigan invest in?

In addition to our accomplished team of executives and industry-leading board of directors, Kardigan launches with $300 million in Series A capital from a strong investor syndicate that includes Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. ...

Where do kardigan's series a funds come from?

The Series A funds come from three prominent venture capital firms: Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. Kardigan, based in South San Francisco and Princeton, N.J., currently has about 60 employees. ...